HACEK Group Infections

Back

Background

The acronym HACEK refers to a group of fastidious gram-negative coccobacillary organisms. HACEK stands for Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella species. The HACEK group accounts for approximately 5%-10% of community-acquired native-valve endocarditis cases in patients who do not use intravenous drugs.[1] HACEK microorganisms grow slowly in standard blood culture media, and recovery may require prolonged incubation.

HACEK organisms are typically oropharyngeal commensals and have long been recognized as a cause of infective endocarditis (IE).[2] Eikenella and Cardiobacterium species have been recovered from the gastrointestinal tract and female genital tract.[3] In addition to infective endocarditis, these organisms have also known to cause wound infections (particularly of bite wounds), soft-tissue abscess, brain abscess, endophthalmitis, parotitis, periodontitis, empyema and bacteremia without endocarditis, and osteomyelitis. In addition, rare cases of endometritis and urinary tract infection have been identified. Invasive infections commonly occur in the setting of trauma, underlying structural heart disease, malignancy, and other immunocompromised states.

Pathophysiology

When introduced into healthy tissue, the HACEK group organisms have the potential for abscess formation and invasive disease. In addition, many examples produce vegetations on infected cardiac valves that are complicated by macroemboli. These vegetations are due to the intrinsic properties of the organisms themselves, the significant delay in diagnosis, or a combination of these two factors. Sixty percent of cases of HACEK IE are associated with various types of dental pathology.

Haemophilus species are pleomorphic gram-negative coccobacilli that require X (hemin) and/or V (nicotinamide adenine dinucleotide) factors for isolation. These substances are found naturally in red blood cells. Haemophilus species are responsible for 0.5%-1% of all cases of IE. Of those, most are due to Haemophilus aphrophilus, followed by Haemophilus parainfluenzae. Haemophilus influenzae rarely causes IE despite its frequency of being involved in bacteremias. Ten percent of cases involve a second pathogen, usually an alpha-hemolytic Streptococcus or Staphylococcus aureus. Endocarditis due to H parainfluenzae has been increasing in frequency. Of these cases, 45% are associated with oral pathology and 10% are associated with upper respiratory tract infections. In 67% of cases, the mitral valve is involved, and in 17%, the aortic valve is involved. Fifty percent of patients have underlying valvular disease.

Thirty-three percent of cases of H aphrophilus IE are due to dental disease, and 20% are due to sinusitis or otitis media. The mitral valve is involved in 56% of patients, and the aortic valve is involved in 33%. Eighty-eight percent of individuals have underlying cardiac disease. Arterial embolization occurs in 31% of cases of H aphrophilus IE.

Actinobacillus actinomycetemcomitans was first isolated in 1912 from skin lesions associated with Actinobacillus israelii. Growth of this bacillus occurs in trypticase soy broth, where it forms granules that float on top or stick to the container. It is the etiologic agent of localized juvenile periodontitis, one manifestation of early-onset periodontitis (EOP).

EOP includes a spectrum of entities in which severe periodontal attachment loss occurs in children, adolescents, and young adults. The ability of this organism to produce gingivitis is based in great part on its production of a leukotoxin and its ability to invade gingival cells. A actinomycetemcomitans, on its own, can mimic most of the clinical syndromes caused by A israelii. Of patients with A actinomycetemcomitans IE, 86% have underlying heart disease and 25% have infection of a prosthetic valve (usually aortic). The aortic valve is involved in 65%, and the mitral valve is involved in 30%. Arterial embolization occurs in 43% of cases.

As opposed to the other members of the HACEK group, C hominis has been isolated almost exclusively from patients with endocarditis. In addition to being part of the normal flora of the mouth and upper airway, it is isolated from the large bowel. However, most C hominis bloodstream infections are secondary to oral pathology. They are gram-negative or gram-variable pleomorphic rods with bulbous swelling of both ends that are characteristically grouped in chains, clusters, or rosettes. Seventy-five percent of cases have underlying heart disease, with 43% involving the mitral valve and 36% the aortic valve. Arterial embolization is documented in 40% of patients.

E corrodens takes its name from its ability to corrode (or pit) the agar during growth. It is a gram-negative pleomorphic, often coccobacillary, rod that exudes a chlorine bleach odor. It is facultatively anaerobic. It is part of the oral flora and many other mucosal surfaces.

E corrodens is usually isolated with other organisms, especially strains of streptococci. This organism is a well-recognized cause of cellulitis resulting from human bites and clenched-fist injuries. It has also been found to be a common cause of soft-tissue infections and endocarditis in drug users. This association may arise from the habit of intravenous drug abusers to lick their needles for good luck. These infections are often complicated by osteomyelitis of the underlying bones. It may produce various pulmonary infections (eg, empyema, pneumonia, septic emboli) that mimic those caused by strict anaerobes. Most patients with E corrodens endocarditis have underlying valve lesions. Compared to cases of IE caused by the other members of the HACEK group, the valvular infections of E corrodens are usually due to intravenous drug abuse.

Kingella species are small gram-negative organisms whose shapes range from those of cocci to those of coccobacilli. This organism can also cause pitting of the agar. The Kingella genus includes 3 species: Kingella kingae, Kingella denitrificans, and Kingella indologenes. IE is usually caused by K kingae. Only approximately 20 cases of endocarditis have been described. Unlike with the other HACEK organisms, Kingella IE progresses quite rapidly.

Epidemiology

Frequency

United States

HACEK organisms are responsible for a small but recognizable percentage (roughly 3%) of endocarditis cases.[4] It is apparent that non-HACEK gram-negative endocarditis is likely increasing in incidence owing to the increased use of endovascular devices.[5] Reporting of these infections has increased, but this may be due simply to increased awareness of the infections among physicians and laboratory personnel, along with new laboratory techniques. Mayo Clinic data suggest the incidence of the HACEK group endocarditis to be 0.14 per 100,000 patient-years.[6]

International

In a prospective multinational cohort study from 64 hospitals in 28 countries, HACEK organisms were isolated in approximately 1.4% of infective endocarditis cases.[2]

For the most part, endocarditis is the focus of incidence studies of HACEK infections, but other infections can be caused by these organisms. By the mid-1980s, 132 cases of H aphrophilus infection had been reported: 55% endocarditis, 15% brain abscess, and the remainder sinusitis, meningitis, pneumonitis, bacteremia, and empyema.

Nineteen cases of Eikenella brain infections were reported through 1983.[7]

Mortality/Morbidity

Infective endocarditis (IE) caused by the HACEK organisms is typically subacute, with the exception of H parainfluenzae endocarditis, which may present more acutely.[8] At the time of presentation, large valvular vegetations are common. Embolization is common and results in significant morbidity.

Mortality rates range from 10%-40% and may vary by organism. Contemporary case series have suggested a modern mortality risk closer to 10%-15%.[6]

The morbidity of IE caused by the HACEK group is similar to that of other types of endocarditis and includes embolization, local extension into the perivalvular area, congestive heart failure (CHF), and regurgitant valve lesions. Compared with all causes of IE, these organisms may be associated with an increased risk of embolization.[9]

Race

No racial differences have been reported in endocarditis caused by the HACEK organisms.

Sex

Older data suggest that HACEK endocarditis has a male predominance. However, there is not enough data available to say that, in the modern era, there is a predilection toward either sex.[10]

Age

The great majority of IE cases caused by HACEK organisms have been reported in older adults. HACEK IE in children with congenital heart disease has been reported.

In children, 70% of Kingella infections involve the skeletal system, predominantly septic arthritis. In a study of K kingae infections in children from southern Israel, Yagupsky and Dagan found that 45% of affected children were aged 13-24 months, with an attack rate of 27 cases per 100,000 children younger than 24 months. Almost 90% of all children with invasive K kingae infections have been younger than 5 years.[11]

Actinobacillus is highly associated with dental disease, being found in 50% of adults with periodontitis and 97% of children with juvenile periodontal disease. In a series of 57 cases of A actinomycetemcomitans endocarditis, poor dentition (46%) and abnormal cardiac valves (60%) were found to be predisposing factors.[12]

Prognosis

The prognosis is quite variable, depending on many factors, such as delay in diagnosis, age of the patient, and occurrence of complications. Patients with uncomplicated IE caused by HACEK organisms generally respond well to therapy and have an excellent prognosis.[6]

History

Most cases of infective endocarditis (IE) caused by the HACEK organisms are subacute. Patients present with progressive symptoms developing over weeks. Some cases have been present for as long as 18 months before the correct diagnosis is made.[10] This delay is often due to failure to use special culture techniques.[13] (See Lab studies.) HACEK IE should be considered in the differential diagnoses of fever of unknown origin.

Fever is common but may be absent in elderly individuals, immunocompromised patients, or patients taking anti-inflammatory drugs. In some series, it was present in only 50% of cases.[10]

Nonspecific symptoms, such as weight loss, anorexia, nausea and vomiting, fatigue, back pain, and night sweats, are common and may lead to a delay in diagnosis.

Patients may have a history of prior valvular disease.

A history of prior dental, urologic, and other procedures should be elicited.

A history of intravenous drug abuse should be elicited.

A sentinel headache may indicate the impending rupture of a mycotic aneurysm.[14]

Brain abscess can manifest as neurologic symptoms, such as focal weakness or numbness, cranial nerve dysfunction, and/or seizure. Primary brain abscess cases have been associated with canine saliva contamination or head and neck wounds.[7, 15]

Human bite or clenched fist injuries can be infected with HACEK organisms and can present as wound and deeper-tissue infections.

Various other presentations, including orbital cellulitis, necrotizing pneumonia, visceral abscess, bacteremia, and thrombophlebitis, have been reported.

Physical

The diagnosis of endocarditis is challenging. The physical findings are often subtle and difficult to identify for many clinicians. Special care should be taken to perform a comprehensive physical examination looking for evidence of endocarditis. Some of the areas to focus on are noted below.[16, 17, 18]

Heart

A new or changing heart murmur is the most consistent physical finding, but it may be absent, especially in right-sided endocarditis.

Peripheral

Because of the increased use of healthcare and diagnostic imaging, the peripheral manifestations of endocarditis are not seen as commonly as they once were.

Examine the patient for clubbing (with or without hypertrophic osteoarthropathy), splinter hemorrhages, mucocutaneous petechiae, Osler nodes, Janeway lesions, and Roth spots.

Splenomegaly can be present.

Embolic complications [19]

A vegetation can embolize to virtually any vessel and can result in various sequelae.

Observe for compromise of circulation to the limbs due to embolization.

Emboli to the central nervous system often presents as a focal neurological deficit or a stroke. Emboli to the frontal lobe may be more subtle, causing personality changes or loss of inhibition.[14]

Emboli to the kidney may cause flank tenderness, hematuria, and/or oliguria.

Embolization to heart vessels can have various manifestations, including acute myocardial infarction and arrhythmia.

A large mesenteric embolus can cause bowel ischemia and thus manifest as abdominal pain and tenderness.

A right-sided vegetation can embolize to the lung and present similarly to a pulmonary embolus or focal pneumonia.

Bone and joint foci can present as osteomyelitis and/or septic arthritis, manifesting as bone or joint tenderness, swelling, or nonhealing wound.

Other clinical manifestations

Other clinical manifestations, such as dental infection, skin and soft tissue infection/abscess, pneumonia/empyema, parotitis, eye infection, and sinus infection, require examination of the involved area, a thorough history, and assessment for underlying comorbidities.

Causes

Patients may have a history of a preceding dental, urologic, or gastroenterologic procedure.[19]

Periodontal disease is a known predisposing factor.

A history of intravenous drug use also should be considered because many drug users clean their needles or venipuncture sites with saliva. Among the HACEK organisms, E corrodens is the bacterium that has been most frequently associated with intravenous drug abuse.[20]

A history of heart valve abnormalities or the presence of a prosthetic heart valve or pacemaker device also predisposes to endocarditis.

A review of literature from Mayo Clinic between 1971 and 1976 identified predisposing factors such as trauma with wound infections, malignancies with abscesses, and congenital heart disease with endocarditis.[21]

Rare case reports have linked wound contamination with canine saliva and subsequent invasive infections, particularly of the head and neck, leading to brain abscess.[15, 22]

Complications

Many complications can result from IE, regardless of the causative organisms.

CHF is the complication of IE that has the greatest impact on prognosis. It may develop acutely from perforation of a valve leaflet, rupture of an infected chordae, valve obstruction, or because of sudden intracardiac shunts from fistulous tracts. When it appears more insidiously, CHF usually develops during the first month of therapy. Any deterioration in heart function should be taken very seriously because operative mortality increases dramatically after frank ventricular decompensation.

Neurologic complications, whether from emboli, abscess, hemorrhage, or arteritis, are the most frequent causes of death in patients with IE. Mycotic aneurysms are usually clinically silent until they rupture. Consider performing a magnetic resonance angiogram or cerebral CT scan to look for aneurysm in patients with subacute IE.

Splenic infarctions can occur in more than one third of patients but are often clinically silent.

Septic or bland emboli may reach the lung in right-sided endocarditis. These may cause pulmonary infarction, pneumonia, and empyema.

Laboratory Studies

When a HACEK organism is suspected, consider consulting a microbiologist so that special attention can be given to the blood culture specimen. Special procedures performed in the microbiology laboratory my improve the chances of isolating the organisms.[13]

Although prolonged incubation is commonly recommended in this setting, current research suggests it is the special laboratory procedures, rather than the time of incubation, that matter most.[13]

Molecular techniques for the detection and identification of microorganisms have been increasingly used for diagnostics in clinical microbiology. Polymerase chain reaction (PCR) of the 16S rRNA genes and sequencing has increased diagnostic yield, although diagnostic sensitivity is difficult to be determined at this time.[23]

Complete cell count may show anemia with or without reactive thrombocytosis. Total white cell count may or may not be increased.

Other inflammatory parameters should include erythrocyte sedimentation rate and C-reactive protein, although these are nonspecific.

Imaging Studies

Echocardiography

Echocardiography plays an important role in the diagnosis and management of endocarditis. Characteristic vegetations, abscesses, new prosthetic-valve dehiscence, or new regurgitant murmur are 4 powerful identifiers of infective endocarditis (IE) (in combination with other clinical criteria).

Transthoracic echocardiography (TTE) has the advantages of being fast and easy to perform. Specificity for vegetations is 98%; however, sensitivity is lower than 60%. TTE views may be inadequate in approximately 20% of the adult population because of obesity, chronic obstructive pulmonary disease, or chest-wall deformities. TTE cannot exclude infection of prosthetic valves, periannular abscess, leaflet perforation, or fistulae.

Transesophageal echocardiography has the advantage of having higher sensitivity for vegetations and greater specificity and sensitivity for perivalvular extension than TTE.

HACEK group organisms typically produce vegetations that are larger than vegetations found in IE due to other organisms, probably because of the longer mean time to diagnosis.

In addition to its diagnostic utility, echocardiography may play a prognostic role. Certain vegetation characteristics are associated with increased risk for embolism and mortality.[24]

CT scanning

CT scanning can be used for diagnosis of soft-tissue or visceral abscess.

MRI

MRI is more sensitive and specific for bone infection.

Procedures

The most common presentation of HACEK endocarditis is an indolent or subacute endocarditis that is cured with an appropriate course of intravenous antibiotics. In cases of less-common acute clinical presentation with perivalvular abscess and rapid hemodynamic deterioration with heart failure, valve replacement may be necessary.[25]

An arterial embolectomy for large emboli may be needed to salvage a limb or viscera.

Surgical interventions such as incision and drainage or abscess evacuation may be needed if clinically prompted.

Histologic Findings

The valvular lesions and vegetations of HACEK IE are very similar to those found in other types of subacute endocarditis, except that the larger size of the vegetations resembles those seen in fungal or staphylococcal disease.[26, 27]

Medical Care

Appropriate antibiotic therapy is key to the management of infective endocarditis (IE) caused by the HACEK organisms (see Medications). The Infectious Disease Society of America (IDSA) recommends the following:[28]

Antibiotic therapy may be fine-tuned when susceptibility data for the causative organism are available.[29]

Complications that arise (eg, heart failure, embolic complications) also require supportive medical therapy.

When treating a clenched fist injury or bite wound infection, HACEK organisms should be kept in consideration. E corrodens is resistant to macrolides, clindamycin, and metronidazole. H aphrophilus is also typically resistant to clindamycin.

Surgical Care

The decision to consider surgical therapy in patients with IE is often challenging and must be made on an individual basis. The following are several accepted indications for surgery in IE:[9]

Consultations

Treatment of HACEK endocarditis requires a multidisciplinary approach.

Consultation with an infectious disease specialist may be helpful for selecting antibiotics, monitoring therapy, and selecting the duration of therapy.

Consultation with a cardiologist may be helpful, especially if transesophageal echocardiography is needed or if CHF develops.

Management of large vegetations or mechanical complications warrants a cardiovascular surgeon's advice.

Consultation with a dentist is indicated if periodontal disease is present.

Diet

No special diet is necessary in patients with HACEK group infections.

Activity

Although there is no evidence-based recommendation for activity levels in patients with endocarditis, it is prudent to keep activity light in the initial phase of treatment.

Prevention

The risk of endocarditis due to HACEK organisms may be reduced by maintenance of good dental hygiene.

Guidelines for infective endocarditis (IE) prophylaxis prior to dental procedures were updated in 2007. Current recommendations support the use of prophylactic antibiotics for high-risk lesions only.

Antibiotic prophylaxis should be considered before oral/dental procedures in patients with high-risk cardiac conditions.[31]

High-risk conditions include the following:

Long-Term Monitoring

Relapse may occur during the first 6 months following the end of treatment. Patients should be counseled and observed regarding relapse.

Further Inpatient Care

Careful clinical observation is the most important aspect of monitoring adequacy of therapy in HACEK group infections. Persistent or recurrent fever may be a sign of treatment failure, but it also may be due to hypersensitivity reactions, thrombophlebitis, or sterile embolization. Observe patients closely for signs of complications, such as embolic events or CHF.

Repeat blood cultures every 48 hours until they become negative.

Fever that lasts longer than 10 days after starting appropriate antibiotics should cause concern.

Causes of persistent fever include drug fever, antibiotic resistance, myocardial or septal abscesses, large vegetations that are difficult to sterilize, and metastatic infection (intracerebral mycotic aneurysms).

Inpatient & Outpatient Medications

In general, the entire course should be with intravenous antibiotics. Once the patient is stable and cultures are negative, completing intravenous therapy on an outpatient basis is reasonable. However, even in the outpatient setting, frequent evaluations are necessary to assess for response to therapy and for drug toxicity.

Although little evidence exists to support its use in this setting, ciprofloxacin could be used in oral form in certain circumstances. However, given the lack of evidence, this be reserved for special circumstances and in consultation with an infectious disease specialist.[9]

Transfer

If HACEK infection is diagnosed early, managing the infection in a center that does not offer cardiovascular surgery services may be possible. However, consider transfer to a health center with complete cardiac and neurological care for any patient at high risk for complications.

If the patient is stable, has good social support, and is afebrile with negative blood cultures, outpatient therapy can then be offered for the remainder of the treatment course.

Medication Summary

Empiric therapy with ceftriaxone or ampicillin-sulbactam is the recommended approach. Fluoroquinolones can be used in the case of allergy or intolerance to the recommended regimen. Treatment duration is 4 weeks for native valve disease and 6 weeks for prosthetic valve disease.

Ceftriaxone (Rocephin)

Clinical Context:  Drug of choice for treatment of endocarditis due to HACEK organisms. Third-generation cephalosporin with broad-spectrum, gram-negative activity. Lower efficacy against gram-positive organisms and higher efficacy against resistant organisms. Arrests bacterial growth by binding to one or more penicillin-binding proteins. No adjustment necessary in persons with renal or hepatic impairment. Dose should be administered postdialysis if undergoing hemodialysis.

Ampicillin and sulbactam (Unasyn)

Clinical Context:  Drug combination of beta-lactamase inhibitor with ampicillin. Interferes with bacterial cell wall synthesis during active replication, causing bactericidal activity against susceptible organisms. Alternative to amoxicillin when unable to take medication orally.

Covers skin, enteric flora, and anaerobes. Not ideal for nosocomial pathogens.

Ciprofloxacin (Cipro)

Clinical Context:  Alternative to ceftriaxone when treating HACEK in patients who are unable to tolerate beta-lactam treatment. Inhibits bacterial DNA synthesis and, consequently, growth.

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Author

Zartash Zafar Khan, MD, FACP, Infectious Disease Consultant

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

John L Brusch, MD, FACP, Assistant Professor of Medicine, Harvard Medical School; Consulting Staff, Department of Medicine and Infectious Disease Service, Cambridge Health Alliance

Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Disclosure: Nothing to disclose.

Additional Contributors

Christian P Sinave, MD, Associate Professor, Department of Medical Microbiology and Infectious Diseases, University of Sherbrooke Faculty of Medicine, Canada

Disclosure: Nothing to disclose.

Isaac P Humphrey, MD, Assistant Professor of Internal Medicine, Uniformed Services University of the Health Sciences; Clinical Assistant Professor of Internal Medicine, Wright State University Boonshoft School of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

Kenneth C Earhart, MD Deputy Head, Disease Surveillance Program, United States Naval Medical Research Unit #3

Kenneth C Earhart, MD is a member of the following medical societies: American College of Physicians, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, and Undersea and Hyperbaric Medical Society

Disclosure: Nothing to disclose.

Barnett Gibbs, MD Assistant Chief, Department of Clinical Trials, Walter Reed Army Institute of Research, Infectious Disease Service, National Capital Consortium; Assistant Professor of Medicine, Uniformed Services University of the Health Sciences

Disclosure: Nothing to disclose.

Mirabelle Kelly, MD Fellow, Department of Microbiology and Infectious Disease, University of Sherbrooke, Canada

Mirabelle Kelly, MD is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

References

  1. Geraci JE, Wilson WR. Symposium on infective endocarditis. III. Endocarditis due to gram-negative bacteria. Report of 56 cases. Mayo Clin Proc. 1982 Mar. 57 (3):145-8. [View Abstract]
  2. Chambers et al. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. PLoS One. 2013. 8 (5):e63181. [View Abstract]
  3. Maia A, Goldstein FW, Acar JF, Roland F. Isolation of Eikenella corrodens from human infections: report of six cases. J Infect. 1980 Dec. 2 (4):347-53. [View Abstract]
  4. Christou L, Economou G, Zikou AK, Saplaoura K, Argyropoulou MI, Tsianos EV. Acute Haemophilus parainfluenzae endocarditis: a case report. J Med Case Rep. 2009 Jul 16. 3:7494. [View Abstract]
  5. Morpeth S, Murdoch D, Cabell CH, Karchmer AW, Pappas P, Levine D, et al. Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med. 2007 Dec 18. 147(12):829-35. [View Abstract]
  6. Das M, Badley AD, Cockerill FR, Steckelberg JM, Wilson WR. Infective endocarditis caused by HACEK microorganisms. Annu Rev Med. 1997. 48:25-33. [View Abstract]
  7. Cheng AF, South JR, French GL. Eikenella corrodens as a cause of brain abscess. Scand J Infect Dis. 1988. 20 (6):667-71. [View Abstract]
  8. Darras-Joly C, Lortholary O, Mainardi JL, Etienne J, Guillevin L, Acar J. Haemophilus endocarditis: report of 42 cases in adults and review. Haemophilus Endocarditis Study Group. Clin Infect Dis. 1997 Jun. 24(6):1087-94. [View Abstract]
  9. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005 Jun 14. 111(23):e394-434. [View Abstract]
  10. Geraci JE, Wilson WR. Symposium on infective endocarditis. III. Endocarditis due to gram- negative bacteria. Report of 56 cases. Mayo Clin Proc. 1982 Mar. 57(3):145-8. [View Abstract]
  11. Yagupsky P, Dagan R. Kingella kingae: an emerging cause of invasive infections in young children. Clin Infect Dis. 1997 May. 24 (5):860-6. [View Abstract]
  12. Tleyjeh IM, Steckelberg JM, Murad HS, Anavekar NS, Ghomrawi HM, Mirzoyev Z, et al. Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota. JAMA. 2005 Jun 22. 293 (24):3022-8. [View Abstract]
  13. Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. Clin Infect Dis. 2005 Dec 1. 41(11):1677-80. [View Abstract]
  14. Kannoth S, Thomas SV. Intracranial microbial aneurysm (infectious aneurysm): current options for diagnosis and management. Neurocrit Care. 2009. 11(1):120-9. [View Abstract]
  15. FAGER CA. An unusual brain abscess: report of a case. Lahey Clin Bull. 1961 Apr-Jun. 12:108-12. [View Abstract]
  16. Paterick TE, Paterick TJ, Nishimura RA, Steckelberg JM. Complexity and subtlety of infective endocarditis. Mayo Clin Proc. 2007 May. 82(5):615-21. [View Abstract]
  17. Yew HS, Chambers ST, Roberts SA, Holland DJ, Julian KA, Raymond NJ, et al. Association between HACEK bacteraemia and endocarditis. J Med Microbiol. 2014 Jun. 63:892-5. [View Abstract]
  18. Chambers ST, Murdoch D, Morris A, Holland D, Pappas P, Almela M, et al. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. PLoS One. 2013. 8(5):e63181. [View Abstract]
  19. Malani AN, Aronoff DM, Bradley SF, Kauffman CA. Cardiobacterium hominis endocarditis: Two cases and a review of the literature. Eur J Clin Microbiol Infect Dis. 2006 Sep. 25(9):587-95. [View Abstract]
  20. Miró JM, del Río A, Mestres CA. Infective endocarditis in intravenous drug abusers and HIV-1 infected patients. Infect Dis Clin North Am. 2002 Jun. 16(2):273-95, vii-viii. [View Abstract]
  21. Bieger RC, Brewer NS, Washington JA 2nd. Haemophilus aphrophilus: a microbiologic and clinical review and report of 42 cases. Medicine (Baltimore). 1978 Jul. 57 (4):345-55. [View Abstract]
  22. Abla AA, Maroon JC, Slifkin M. Brain abscess due to Haemophilus aphrophilus: possible canine transmission. Neurosurgery. 1986 Jul. 19 (1):123-4. [View Abstract]
  23. Lisby G, Gutschik E, Durack DT. Molecular methods for diagnosis of infective endocarditis. Infect Dis Clin North Am. 2002 Jun. 16 (2):393-412, x. [View Abstract]
  24. Thuny F, Di Salvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation. 2005 Jul 5. 112(1):69-75. [View Abstract]
  25. Patrick WD, Brown WD, Ian Bowmer M, Sinave CP. Infective endocarditis due to Eikenella corrodens: Case report and review of the literature. Can J Infect Dis. 1990 Winter. 1 (4):139-42. [View Abstract]
  26. Trexler Hessen M, Abrutyn E. Gram-Negative Bacterial Endocarditis. Kaye D, ed. Infective Endocarditis. 2nd ed. New York, NY: Raven Press; 1992. 251-64.
  27. Yamamoto S, Hosokawa N, Sogi M, Inakaku M, Imoto K, Ohji G, et al. Impact of infectious diseases service consultation on diagnosis of infective endocarditis. Scand J Infect Dis. 2011 Dec 18. [View Abstract]
  28. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015 Oct 13. 132 (15):1435-86. [View Abstract]
  29. Coburn B, Toye B, Rawte P, Jamieson FB, Farrell DJ, Patel SN. Antimicrobial susceptibilities of clinical isolates of HACEK organisms. Antimicrob Agents Chemother. 2013 Apr. 57(4):1989-91. [View Abstract]
  30. Evans CF, Gammie JS. Surgical management of mitral valve infective endocarditis. Semin Thorac Cardiovasc Surg. 2011 Autumn. 23(3):232-40. [View Abstract]
  31. [Guideline] Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Oct 9. 116(15):1736-54. [View Abstract]
  32. Ferreiros E, Nacinovich F, Casabé JH, Modenesi JC, Swieszkowski S, Cortes C, et al. Epidemiologic, clinical, and microbiologic profile of infective endocarditis in Argentina: a national survey. The Endocarditis Infecciosa en la República Argentina-2 (EIRA-2) Study. Am Heart J. 2006 Feb. 151(2):545-52. [View Abstract]
  33. Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. Clin Infect Dis. 2005 Dec 1. 41(11):1677-80. [View Abstract]
  34. Bayer AS, Scheld WM. Endocarditis and intravascular infections. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease. 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000. 857-902.
  35. Berbari EF, Cockerill FR, Steckelberg JM. Infective endocarditis due to unusual or fastidious microorganisms. Mayo Clin Proc. 1997 Jun. 72(6):532-42. [View Abstract]
  36. Goutzmanis JJ, Gonis G, Gilbert GL. Kingella kingae infection in children: ten cases and a review of the literature. Pediatr Infect Dis J. 1991 Sep. 10(9):677-83. [View Abstract]
  37. [Guideline] Gustke CJ. A review of localized juvenile periodontitis (LJP): II. Clinical trials and treatment guidelines. Gen Dent. 1998 Nov-Dec. 46(6):580-7; quiz 588-9. [View Abstract]
  38. Gustke CJ. A review of localized juvenile periodontitis (LJP): Part I. Clinical features, epidemiology, etiology, and pathogenesis. Gen Dent. 1998 Sep-Oct. 46(5):491-7. [View Abstract]
  39. Lampe AS, Schroijen MA, Smith SJ. [Endocarditis due to Aggregatibacter (formerly: Actinobacillus) actinomycetemcomitans, a bacterium that grows in characteristic star-shaped colonies]. Ned Tijdschr Geneeskd. 2008 Apr 5. 152(14):827-30. [View Abstract]
  40. Parker SW, Apicella MA, Fuller CM. Hemophilus endocarditis. Two patients with complications. Arch Intern Med. 1983 Jan. 143(1):48-51. [View Abstract]
  41. Pereira RM, Bucaretchi F, Tresoldi AT. Infective endocarditis due to Haemophilus aphrophilus: a case report. J Pediatr (Rio J). 2008 Mar-Apr. 84(2):178-80. [View Abstract]
  42. Weinstein L, Brusch JL. Gram-Negative and Other Organisms. Weinstein L, Brusch JL, eds. Infective Endocarditis. New York, NY: Oxford University Press; 1996. 73-122.
  43. Westling K, Vondracek M. Actinobacillus (Aggregatibacter) actinomycetemcomitans (HACEK) identified by PCR/16S rRNA sequence analysis from the heart valve in a patient with blood culture negative endocarditis. Scand J Infect Dis. 2008. 40(11-12):981-3. [View Abstract]
  44. Kaplan AH, Weber DJ, Oddone EZ, Perfect JR. Infection due to Actinobacillus actinomycetemcomitans: 15 cases and review. Rev Infect Dis. 1989 Jan-Feb. 11 (1):46-63. [View Abstract]